Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Changing the landscape for clinical trials by developing a major centre in the UK.


We are entering a new era of treatments for rare, genetic conditions like muscular dystrophy. Progress in the search for effective treatments and cures is being made in the UK and across the world.

But, as research continues to gain momentum – moving us closer to treatments – so does the demand for clinical trials.

The number of clinical trials being undertaken in the UK is increasing but inadequate capacity – such as a lack of infrastructure and expertise – means centres are struggling to meet demand.

We are aware that centres have been forced to turn down some clinical trials for muscle-wasting conditions in the UK.

Unless these capacity issues are resolved across the UK, we will see reduced opportunities for patients to be enrolled in clinical trials. In order for the UK to remain one of the key countries for clinical trials for neuromuscular conditions, additional capacity must be addressed.

We believe everyone has the right to live life to the fullest. That’s why we’re working with Oxford University to establish a world-leading centre aimed at bringing new treatments to patients more quickly.

The MDUK Oxford Neuromuscular Centre will boost capacity for clinical trials. Working alongside the major centres in Newcastle and London, this third centre will be a game changer for individuals and families living with muscle-wasting conditions in the UK.


Read more on the MDUK website.